Analysts expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to report earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Pieris Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.12). Pieris Pharmaceuticals posted earnings of $0.17 per share in the same quarter last year, which indicates a negative year over year growth rate of 194.1%. The firm is scheduled to announce its next quarterly earnings results on Friday, March 8th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts expect that the business will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.07) to ($0.62). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.16 million. Pieris Pharmaceuticals had a negative return on equity of 18.07% and a negative net margin of 17.90%.
A number of equities analysts have weighed in on the company. BidaskClub upgraded Pieris Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 26th. HC Wainwright set a $12.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Cowen restated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Sunday, November 11th. Finally, ValuEngine lowered Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $10.00.
Shares of NASDAQ PIRS opened at $3.39 on Monday. The stock has a market capitalization of $183.57 million, a price-to-earnings ratio of -8.48 and a beta of 1.94. Pieris Pharmaceuticals has a twelve month low of $3.04 and a twelve month high of $9.75.
In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy bought 5,000 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were acquired at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $51,100. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 5.07% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in PIRS. Public Employees Retirement System of Ohio bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $110,000. Marshall Wace LLP bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $118,000. Bowling Portfolio Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $156,000. California Public Employees Retirement System bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $179,000. Finally, Alpine Global Management LLC increased its position in shares of Pieris Pharmaceuticals by 125.0% during the 2nd quarter. Alpine Global Management LLC now owns 45,000 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 64.85% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.